We are Glytherix

Developer of cancer therapeutics

Developing a new drug – Miltuximab®

GlyTherix Ltd is an Australian immuno-oncology company specializing in therapeutics for solid tumors, including prostate, bladder and pancreas. GlyTherix is developing Miltuximab® for the targeted treatment of a number of cancers. At the core of the technology is a protein known as Glypican-1 (GPC-1). GPC-1 occurs in many solid tumors such as prostate, bladder, pancreatic, glioblastoma, esophageal, ovarian and brain cancers. It is not present in healthy tissue.

The company has a strong proprietary and Intellectual Property position covering both Miltuximab®, its anti-GPC-1 antibody and the antigen itself, GPC-1. This provides robust and long-term protection for the commercialization of important new treatments to people with little hope of cure. GlyTherix has now completed a ‘First-in-Human’ trial of 12 patients using Miltuximab® with no drug-related adverse events observed. GlyTherix is interested in partnerships or collaborations with larger pharmaceutical partners.

GlyTherix has:

– The ability to address a clear market need for new therapies to target solid tumors.

– A clear development pathway.

– A clear understanding of the requirements for the pipeline development programs.

– The leadership team needed to manage the planned research programs.

– A clear end goal which is to maximize the return on its intellectual property assets.

Miltuximab® is a first in class product. No-one else presently has an antiglypican-1 therapy, in clinical development, for these cancers.

For any antibody-based therapy one should not only be the first but also the best in class. To achieve this GlyTherix is developing pipeline with:

  • The best version of the antibody; which is most effective and safe as well as acceptable to our future licensee partners.
  • The best cell killing payload; which is most effective and well tolerated by the patient.

The company has also developed Glytuzumab® a humanized antibody targeting GPC-1.

GlyTherix is raising capital to fund the commercialization of Miltuximab®, that targets cancers that have a major underserved need, in a high-value market, with the protection of a growing intellectual property position (5 families of applications) and a reduced commercial risk profile.

Headquarters in Australia

We are based in Sydney, adjacent to one of Australia’s leading universities, Macquarie University, and the Macquarie University Hospital, one of our key collaborators.

Our reach is global, through partnerships with universities, research institutes, and companies.

Extensive intellectual property

GlyTherix owns an extensive patent estate protecting our distinctive technology. All the intellectual property relevant to our technology is owned by us.

Advances in therapeutics and imaging

Advanced trials are underway using our technologies to target tumors for treatment and imaging of cancers. Read more.
Contact us to discuss registration and commercialization of future therapeutic applications.

Headquarters in Australia

Suite 2, Ground Floor, 
75 Talavera Road, 
Macquarie Park, NSW 2113, 

International +612 9850 4000
In Australia 02 9850 4000
Compare your time zone with Sydney here


Finding Us
We are based in Sydney, adjacent to one of Australia’s leading universities, Macquarie University, and the Macquarie University Hospital, one of our key collaborators.

Headquarters of Minomic

Privacy Policy